Catherine C. Turkel, Director at Lexaria Bioscience Corp. (LEXX), bought 1,500 shares at $2.84 ($4K) on 2023-02-09, disclosed to the SEC on 2023-02-27.
Open-market purchase of $4k LEXX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| NVUS | BUY | 2018-09-13 | $322K | — | Filing → |
| NVUS | BUY | 2018-09-07 | $3K | — | Filing → |
| NVUS | BUY | 2017-05-11 | $222K | — | Filing → |